https://doi.org/10.4081/hmr.v2i5.737

Monoclonal antibodies (novel): humax-CD20, ofatumumab

Vol. 2 No. 5: New Drugs in Hematology, Bologna, Italy 5-7 October 2008
Published: June 23, 2009
Abstract Views: 177
PDF: 204
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

A Hagenbeek
support@pagepress.org
Ofatumumab, the first fully human anti-CD20 monoclonal antibody, targets a novel epitope of the CD20 molecule on B-cells and releases only very slowly from the target compared with rituximab. The antibody is generated via transgenic mouse and hybridoma technology. Compared with rituximab, ofatumumab has similar ADCC, but stronger CDC, even to lymphoma cells with a low CD20 antigen density and a high number of CD55 and CD59 complement inhibitory molecules present in the cell membrane. In addition, ofatumumab kills fresh B-CLL cells resistant to rituximab. In the cynomolgus monkey model, the ofatumumab-depletion of B-cells from peripheral blood and lymph nodes lasted longer than the depletion induced by rituximab. Given the above, ofatumumab has the potential to treat B-cell malignancies with low CD20 expression, such as B-CLL and rituximab-refractory follicular lymphoma.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Hagenbeek, A. (2009). Monoclonal antibodies (novel): humax-CD20, ofatumumab. Hematology Meeting Reports (formerly Haematologica Reports), 2(5). https://doi.org/10.4081/hmr.v2i5.737
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).